Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Horvath, Dennis; Termperton, Nigel; Mayora-Neto, Martin; Da Costa, Kelly; Horlacher, Reinhold; Günther, Armin; Brosig, Alexander; Morath, Jenny; Jakobs, Barbara; Groettrup, Marcus; Hoschuetzky, Heinz; Rohayem, Jacques; ter Meulen, Jan

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
Hōputu:	Tuhinga
Reo:	Ingarihi
I whakaputaina:	Philipps-Universität Marburg 2023
Ngā marau:	Immunology Medizin Biotechnology Microbiology Medical sciences Medicine
Urunga tuihono:	Kuputuhi katoa PDF
Tags:	Tāpirihia he Tūtohu Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Ngā tūemi rite